Ipsen Upbeat Despite Palovarotene Pain
Healthy Sales Rise In 2019
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.
